<DOC>
	<DOC>NCT00095498</DOC>
	<brief_summary>This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Diagnosis of RA. All subjects will be required to have been taking a stable dose of methotrexate. Active RA at screening defined as greater than or equal to 6 swollen joints. The presence of erosive disease Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed. Steroid use greater than 15 mg/day. Scheduled for surgery or joint replacement in the hands, wrists or feet.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>arthritis</keyword>
	<keyword>joint pain</keyword>
	<keyword>Methotrexate</keyword>
</DOC>